Business Wire

CA-VELODYNE-LIDAR,-INC.

15.11.2018 14:02:11 CET | Business Wire | Press release

Share
Automotive Innovator, Rick Tewell, Promoted to Chief Operating Officer at Velodyne Lidar

Velodyne Lidar, Inc. announces the promotion of Rick Tewell to Chief Operating Officer. Tewell assumes leadership of the company’s vast manufacturing efforts at its Megafactory in San Jose, California. He joined the company in September 2017 as Senior Vice President of Automated Manufacturing and was promoted to Chief Advanced Manufacturing Officer prior to the promotion to COO. He brings a wealth of expertise to the day-to-day production of Velodyne’s industry-leading lidar sensor product line.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005168/en/

According to Marta Hall, Velodyne’s President and Chief Business Development Officer, Velodyne “recruited Rick Tewell to manage Robotics and Advanced Technology, and within a year it was clear he could lead Operations as COO. Velodyne Lidar is at the extreme edge of high tech, and Rick meets the challenge with da Vinci-like multiple talents. In the last three months Rick upgraded the entire Velodyne Megafactory with robotics and newly designed innovative processes for production. As COO he brings a futuristic vision and fresh energy to the operations of the company.”

“My main responsibility,” said Tewell, “is to take a design that came from the mind of a genius, David Hall [Velodyne’s Founder and CEO], and make it into a product worthy of the Velodyne name. I work with David and Anand [Gopalan, Velodyne’s Chief Technology Officer] to translate these wonderful designs that have the ability to change the world into something that is manufacturable and then ramp production to meet the demand. To take an invention from Dave Hall and turn it into a manufacturable product is a huge responsibility and one that I take very seriously. It’s an incredible opportunity. I get out of bed excited to go to work, and I go to bed thinking about it.”

According to Tewell, the job of Chief Operating Officer at Velodyne is unlike any other. Between designing and manufacturing the highest quality sensors on the market comes the equally challenging task of inventing and building the machines that then build the sensors.

“For our sensors to be able to see so far and produce incredibly accurate data for autonomous vehicles to use, we have to employ incredibly precise processes, which include utilizing robotics and automation. So we need to also invent the machines that will build our sensors.” Given the uniqueness of Velodyne’s products, Tewell pointed out that he must address the complex processes of “taking something that’s never been invented or built before and building tens of thousands -- hundreds of thousands -- millions of them. It is a whole series of inventions to produce the sensor invention. So, it is not just the genius of the lidar itself; it’s the genius of saying, ‘This is what you are going to need to invent in order to manufacture the sensor.’”

Before coming to Velodyne, Tewell established a successful career in the automotive semiconductor industry, including stops at Fujitsu and NVIDIA. Rick remembers, “The idea that cars eventually would be robots emerged while Dave Hall was participating in the DARPA Grand Challenge. At NVIDIA we were creating the brains that would be used in self-driving cars.” Tewell’s interest and experience in developing key technologies for autonomous mobility grew over the years. Finally, Tewell decided to join Velodyne with the clear realization that he would be “aligning with a company that will be one of, if not the, principal company in the self-driving industry.”

Tewell recognizes the essential role Velodyne’s products have in enabling safe mobility at scale. “We are working hard to meet the next wave of demand for sensors to put on autonomous vehicles. Scaling up will drive the cost down to where the price is attractive to all customers. But we will never compromise on quality. It is critical from an operations standpoint that our product will ultimately impact someone’s life. This realization needs to permeate every aspect of what we do. This is not a piece of technology that is going to stay in a box. When you put a sensor on a car the person in that car is trusting that technology to keep them safe.”

About Velodyne Lidar

Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D lidar computing and software platforms. The company evolved after founder David Hall invented the HDL-64 Solid-State Hybrid lidar sensor in 2005. Since then, Velodyne Lidar, Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, the new VLS-128, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit http://www.velodynelidar.com .

Contact:

David Cumpston Landis Communications for Velodyne Lidar, Inc. (415) 359-2316 velodyne@landispr.com

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye